Zealand Pharma Target Resets: Analysts Split on Upside and Risk
Analysts at JPMorgan have lowered their price target for Zealand Pharma (CPSE:ZEAL) to DKK 460 from higher prior levels, while other estimates cluster around DKK 300, reflecting a split view on the stock's prospects after target resets and clinical trial updates.
Key Numbers
Zealand Pharma (CPSE:ZEAL) has seen a wave of price target adjustments from analysts, most notably JPMorgan's reduction to DKK 460 from higher prior levels. Other estimates cluster around DKK 300, highlighting a clear divergence in analyst views on the Danish biotech firm.
Rating Change
JPMorgan lowered its price target for Zealand Pharma to DKK 460, compared to higher prior levels. Meanwhile, a cluster of analyst estimates centers around DKK 300, indicating significant valuation disparity.
Analyst Rationale
Bullish analysts see room for upside based on a modeled fair value of DKK 525.73 (up from DKK 519.07). The cautious camp focuses on execution risks and a thin margin of safety after target resets and trial updates.
Context
The split comes amid important clinical developments at Zealand Pharma, prompting some analysts to reassess risks and opportunities. The stock currently trades below the average target price, but the wide gap between estimates reflects uncertainty.
What to Make of It
The recent target adjustments present a mixed picture for investors. While the modeled fair value suggests potential upside, the focus on execution risk justifies a cautious stance. Investors are advised to monitor clinical trial developments closely to gauge the future direction.
Frequently Asked Questions
Found this useful? Share it